TG Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
TG Therapeutics Stock Forecast and Price Target
The average price target for TG Therapeutics's stock set by six recognized analysts recently is $34.00, which would result in a potential upside of approximately 144.43% if it reached this mark. The estimation is based on a high estimate of $45.00 and a low estimate of $7.00. If you're interested in TGTX stock, it's important to compare it to other companies in the industry.
144.43% Upside
TG Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
TG Therapeutics's Price has grown In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $14.97 – an increase of 100.00%. For the next seven years, experts predict that TG Therapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF90.00 | Buy/Sell | CHF105.00 | 19.58% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.62€ | Buy/Sell | 102.80€ | 18.97% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.70 | Buy/Sell | $58.15 | 21.92% |
| MRK Stock Forecast | Merck KGaA | Outperform |
18
|
150.10€ | Buy/Sell | 190.06€ | 21.92% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$202.46 | Buy/Sell | $299.62 | 42.50% |
TG Therapeutics Revenue Forecast for 2023 - 2025 - 2030
TG Therapeutics's Revenue has grown In the last three years, rising from $150.00k to $233.66M – a growth of 155673.33%. In the next year, analysts believe that Revenue will reach $249.86M – an increase of 6.93%. For the next seven years, experts predict that TG Therapeutics's Revenue will grow at a rate of 640.56%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.90€ | Buy/Sell | 45.15€ | 11.52% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr1.92k | Buy/Sell | kr2.71k | 33.91% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.25 | Buy/Sell | $11.59 | 20.75% |
.jpg)
TG Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's EBITDA has grown, moving from $-273.44M to $20.86M – an increase of 107.63%. 3 analysts predict TG Therapeutics's EBITDA will decrease by 36.58% in the next year, reaching $13.23M. Looking ahead to seven years, experts forecast that EBITDA will grow by 132.43%.
TG Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's EBIT has seen an increase, rising from $-273.59M to $20.63M. This represents a growth of 107.54%. For the following year, the 8 analysts predict that TG Therapeutics's EBIT will drop by 82.94%, reaching $3.52M. Over the next seven years, experts predict that TG Therapeutics's EBIT will grow at a rate of 5405.57%.
TG Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
TG Therapeutics's EPS has grown In the last four years, rising from $-2.42 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $0.02 – an increase of 100.00%. For the next seven years, experts predict that TG Therapeutics's EPS will grow at a rate of 100.00%.
.jpg)